Erratum to: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease  by unknown
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PORRECTION
um PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin
esistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961–965.
n this article, the maximum platelet aggregation values (second replicate values) rather than the mean of the duplicate values were reported
or both adenosine diphosphate and arachidonic acid. The data, as published, are correct for calculations of aspirin resistance and clinical
vents when the maximum platelet aggregation data are used. When the mean values are used, the original aspirin resistance prevalence
f 5.5% becomes 2.8%, because 8 borderline aspirin resistance patients no longer meet the strict criteria for aspirin resistance. The
ercentage of patients with death/myocardial infarction/cerebrovascular accident in the 2 groups remains virtually the same as published,
ith a higher frequency of aspirin resistance patients (2 of 8; 25%) with adverse outcome versus non-aspirin resistance patients (36 of 307;
1.7%). However, due to the lower number of aspirin resistance patients, the difference is no longer statistically significant (p 0.25). The
evised multivariate analysis using mean aggregation values still shows aspirin resistance to be an independent predictor of long-term
dverse events (hazard ratio 5.07, 95% confidence interval 1.16 to 22.22, p  0.03).
hese changes do not affect the Discussion or Conclusions of this article. The authors regret the error.
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